Tanaka, Sakae
Adachi, Taiji
Kuroda, Tatsuhiko
Nakamura, Toshitaka
Shiraki, Masataka
Sugimoto, Toshitsugu
Takeuchi, Yasuhiro
Saito, Mitsuru
Bilezikian, John P
Article History
Received: 8 October 2014
Revised: 24 October 2014
Accepted: 26 October 2014
First Online: 16 December 2014
Competing interests
: ST is on the advisory board of Merck Sharp & and receives lecture fees from Daiichi Sankyo, Eisai, Chugai Pharmaceutical, Asahi Kasei Pharma and Ono Pharmaceutical. TA has no financial interests or conflicts of interest to disclose. TK is an employee of Asahi Kasei Pharma Corporation. TNreceived research grants and/or consulting fees from Chugai Pharmaceutical, Teijin Pharma, Asahi Kasei Pharma and Daiichi Sankyo. MS received consulting fees from Chugai, Daiichi Sankyo, Asahi Kasei Pharma, Teijin Pharma and MSD. TS received consulting fees from Asahi Kasei Pharma and research grants from Eli Lilly Japan, Chugai Pharmaceutical Co, Eisai and MSD. YT received research grants and/or consulting fees from Eli Lily Japan, Chugai Pharmaceutical, Teijin Pharma, AsahiKasei Pharma and Daiichi Sankyo.MiS received consulting fees from Daiichi Sankyo, Asahi Kasei Pharma and Eli Lilly. JPB is a consultant for Amgen, Eli Lilly, Radius, NPS Pharmaceuticals, Merck and GSK and receives research support from NPS Pharmaceuticals and Amgen.